ABCL
AbCellera Biologics Inc. (ABCL) PESTLE Analysis Analysis (2026)
Overall Score
Political
No major political or regulatory catalyst is evident in the latest data.
The company’s cash-rich balance sheet and low debt reduce sensitivity to policy shocks.
Economic
Valuation remains extremely rich at 52.5x sales, leaving the stock sensitive to macro risk and execution misses.
Liquidity is strong with a 12.8 current ratio and 2.26 cash ratio, but profitability and cash flow remain negative.
Social
No new social or demand-shift signal appears in the fresh data.
The business still appears supported by a large gross margin base, but adoption and monetization remain unproven at scale.
Technological
R&D intensity remains very high at nearly 3.0x revenue, indicating continued investment in platform and pipeline development.
The company’s operating losses suggest technology investment has not yet translated into operating leverage.
Legal
No new litigation or compliance issue is indicated in the latest news flow.
Low leverage and strong liquidity reduce near-term legal/financing stress risk.
Environmental
No material environmental development is visible in the current update.
Capital intensity remains manageable, with capex below depreciation, limiting near-term environmental compliance pressure.
Sources
- Company filings (10-K, 10-Q, investor presentations)
- Financial and market data providers
- Public news and industry information
🔒 Go Beyond This Framework
This is one of 10 institutional-grade frameworks Invetso runs on AbCellera Biologics Inc.. Unlock the complete analysis — SWOT, Economic Moat, Porter’s Five Forces, Management, PESTLE and the Invetso Quality Score.

